4/A: KALA Bio Executive Corrects Share Ownership in Amended SEC Filing

A KALA Bio executive filed an amended SEC Form 4 to correct the number of shares beneficially owned after a previous filing error.

Summary

• Romulus K. Brazzell, Head of Research and Development and Chief Medical Officer at KALA Bio, filed an amended Form 4 with the SEC.
• The amendment corrects a previous filing on January 7, 2025, which incorrectly stated the number of shares owned.
• The corrected filing shows that Brazzell directly owns 91,636 shares of common stock, including 62,961 unvested restricted stock units.
• The previous filing had incorrectly reported 92,418 shares owned.

Sentiment

Score: 6

Explanation: The document is a routine correction of a previous filing error. It doesn't indicate any significant positive or negative news, but the error does introduce a minor negative sentiment.

Negatives

• The need for an amended filing indicates an initial error in reporting share ownership.

Risks

• Errors in SEC filings can raise concerns about internal controls and accuracy of financial reporting.

Industry Context

This type of filing is routine for company insiders who have transactions in company stock. The amendment highlights the importance of accurate reporting to the SEC.

Comparison to Industry Standards

• SEC Form 4 filings are a standard requirement for company insiders across all publicly traded companies.
• The need for an amendment is not uncommon, but it does highlight the importance of accuracy in these filings.
• Companies like Amgen, Regeneron, and Biogen also have similar filings when their executives trade company stock.

Stakeholder Impact

• The correction of the filing ensures that shareholders have accurate information about insider ownership.

Key Dates

Keywords

SEC Filing, Form 4, Beneficial Ownership, KALA Bio, Share Ownership, Amendment, Restricted Stock Units